No Data
No Data
Rein Therapeutics Awarded to Patents Related to LTI-03
Express News | Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder Lti-03 for the Treatment of Respiratory Diseases
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
Rein Therapeutics' LTI-2355 Peptide Shows Therapuetic Potential in Study
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Aileron Therapeutics Non-GAAP EPS of -$0.26 Beats by $0.22